Xocova tablets drug use-results survey

Xocova tablets drug use-results survey - Xocova tablets drug use-results survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049727

Enrollment

3000

Registered

2022-12-08

Start date

2022-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2 infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: SARS-CoV-2 infected patient who has not been treated with Xocova tablets and provides an informed consent in written for data collection and analysis

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety Incidence of adverse drug reactions	—

Secondary

Measure	Time frame
Clinical outcome Time to resolution of COVID-19 symptoms in SARS-CoV-2 infected patients The number and rate of hospitalization for COVID-19 or death from any cause through day 28	—

Countries

Japan

Contacts

Public ContactSatoru Takashima

Shionogi & Co., Ltd. Pharmacovigilance Department

satoru.takashima@shionogi.co.jp+81-6-6209-6929

Outcome results